
Mycobacterium bovis Infection: High Requirement for Surgical Interventions in HIV-Infected Subjects

[Sergio Zuñiga-Quiñones](#) , [Pedro Martínez-Ayala](#) , [Montserrat Álvarez-Zavala](#) ,
[Isaac Dante Vladimir Garcia-Govea](#) , [Luz Alicia González-Hernández](#) , [Jaime Federico Andrade-Villanueva](#) ,
[Fernando Amador-Lara](#) *

Posted Date: 27 April 2025

doi: 10.20944/preprints202504.2224.v1

Keywords: *Mycobacterium bovis*; Zoonotic tuberculosis; *Mycobacterium tuberculosis*; HIV infection



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Article

M. bovis Infection: High Requirement for Surgical Interventions in HIV-Infected Subjects

Sergio Zuñiga-Quiñonez ^{1,2}, Pedro Martinez-Ayala ^{1,2}, Monserrat Alvarez-Zavala ^{1,2}, Isaac D.V. Garcia-Govea ³, Luz A. Gonzalez-Hernandez ^{1,2}, Jaime F. Andrade-Villanueva ^{1,2} and Fernando Amador-Lara ^{1,2,*}

¹ Departamento de Clínicas Médicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44280, México; infectologosergio@gmail.com (S.Z.-Q.); pemayala4@gmail.com (P.M.-A.); monse_belan@hotmail.com (M.A.-Z.); luceroga08@gmail.com (L.A.-G.); drjandradev@gmail.com (J.F.A.-V.); fernando.amador@academicos.udg.mx (F.A.-L.)

² Unidad de VIH, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, 44280, México

³ Departamento de Medicina Interna, Instituto Mexicano del Seguro Social; Guadalajara, 44329, México; dante.garcia@alumno.udg.mx (I.D.V.-G.-G.)

* Correspondence: fernando.amador@academicos.udg.mx

Abstract: Background: Zoonotic *Mycobacterium bovis* infection continues to occur, particularly in regions where there is no surveillance for bovine tuberculosis and raw milk consumption is common, or dairy products, including artisanal cheeses, are marketed unpasteurized. We describe the clinical and microbiological characteristics, procedures and treatment outcomes of subjects with *M. bovis* infection in HIV-infected individuals. **Methods:** A retrospective study was conducted obtaining the sociodemographic and clinical data, microbiological characteristics, CT findings and outcomes of 12 subjects with *M. bovis* infection which were compared these characteristics of 14 individuals with *M. tuberculosis* infection in HIV-infected subjects in the same period. **Results:** We found a significantly increased risk of *M. bovis* transmission due to consumption of unpasteurized dairy products and higher CD4+ T cells count in subjects with *M. bovis* infection vs *M. tuberculosis* infection ($p < 0.0001$ and 0.01 respectively). All subjects with *M. bovis* infection had extrapulmonary involvement. CT findings in *M. bovis* infection that were significantly more frequent vs *M. tuberculosis* infection were retroperitoneal lymphadenopathy, hepatosplenomegaly, and splenic abscesses. The site of microbiological identification was extrapulmonary in all *M. bovis*-infected subjects. Surgical interventions such as surgical drainage of abscesses or splenectomy were required significantly more frequently in subjects with *M. bovis* infection ($p = 0.0003$). **Conclusions:** Extrapulmonary involvement, particularly with abdominal involvement, is routinely present in *M. bovis* infection in HIV-infected individuals. Surgical interventions are frequently required for diagnosis and management. Efforts to identify *M. bovis* should be made, particularly in high-burden regions.

Keywords: *Mycobacterium bovis*; Zoonotic tuberculosis; *Mycobacterium tuberculosis*; HIV infection

1. Introduction

Zoonotic tuberculosis (zTB), a form of human tuberculosis is caused primarily by *M. bovis*, a mycobacterial specie belonging to the *Mycobacterium tuberculosis* complex (MTBC) [1]. Estimates of the number of cases and deaths from zTB are imprecise. According to WHO, around 140,000 new cases and 11,400 deaths were due to zTB worldwide in 2019 [2]. Globally, the prevalence of zTB is around 1.4% among all tuberculosis (TB) cases, however, the disease is underreported mostly in resource-limited countries due to lack of systematic surveillance and limited diagnostic capacities to distinguish TB caused by *M. tuberculosis* or *M. bovis* which requires mycobacterial culture and subsequent use of biochemical or molecular diagnostic methods [3–5].

Consumption of unpasteurized milk and dairy products represents the main route of transmission of *M. bovis* [6,7]. In middle and low-income countries, pasteurization is less implemented. In Mexico, almost 30% of the milk produced is sold unpasteurized, including that used for making artisanal cheese[8]; and in many African countries, pasteurization of milk is not carried out regularly and 80-90% of the milk produced is sold by small daily farms and pastoral communities[9]. The artisan cheese making process, which usually uses raw milk, does not eliminate the *M. bovis* bacillus and several studies have found the presence of *M. bovis* in artisanal cheeses through culture and molecular methods [10–13].

Bovine TB is endemic in several countries, data from 119 countries report having *M. bovis* circulating in their cattle in 59% of them, but only 10% have implemented zTB surveillance activities [14]. The lack of surveillance of bovine TB in countries with a high burden and the absence of test-and-slaughter policies in infected cattle increases transmission to humans [15].

Although human-to-human transmission of *M. bovis* might be less effective than *M. tuberculosis* due to three mutations affecting the two-component virulence regulation system PhoP/PhoR [16], outbreaks of *M. bovis* infection have been reported including multidrug resistant, especially in HIV-positive patients associated to high mortality [17–19].

In many regions of the world, especially in low-income countries, the diagnosis of TB is based on sputum smear microscopy or rapid assays as Xpert MTB/RIF®, this diagnostic tool recommended by the WHO since 2010, is considered an important breakthrough in the fight against tuberculosis globally and despite its solid evidence supporting its wide use in the detection of pulmonary and extrapulmonary tuberculosis, as well as mutations in the *rpoB* gene that confers rifampicin resistance [20], the assay identifies MBTC but cannot differentiate *M. tuberculosis* from *M. bovis*, so if the diagnosis is based only on Xpert MTB/RIF® positivity without identifying the species either by culture to molecular methods leaves *M. bovis* infection underdiagnosed and misclassified [21].

The aim of this study is to describe the clinical, microbiological characteristics, CT findings, surgical intervention and treatment outcomes of subjects with *M. bovis* infection compared with individuals with *M. tuberculosis* infection in HIV-infected subjects during the same period.

2. Materials and Methods

2.1. Design

This was a retrospective study conducted in Guadalajara, Jalisco, México from January 2019 to March 2023. Data were obtained from the database of the HIV Unit of the Hospital Civil de Guadalajara, approved by the hospital's Ethics Committee.

Sociodemographic data, comorbidities, clinical and microbiological characteristics (symptoms, anatomical site of infection, site of isolation/identification, diagnostic method), computed tomography (CT) imaging findings, surgical interventions performed, and treatment outcomes from HIV-infected subjects diagnosed with *M. bovis* infection through culture and/or polymerase chain reaction (PCR) were collected and compared with cases of *M. tuberculosis* infection, diagnosed by culture and PCR in HIV-infected individuals during the same period. Patients with *M. tuberculosis* infection received treatment according to World Health Organization tuberculosis treatment guidelines[22]. For patients with *M. bovis* infection, a fluoroquinolone (levofloxacin) was included in the regimen, due to the intrinsic resistance of *M. bovis* to pyrazinamide.

2.2. Statistical Analysis

Categoric variables were summarized using counts and percentages and medians and interquartile range or mean, and standard deviation were used for continuous variables. Qualitative variables were analyzed using Fisher's exact test. Quantitative variables were analyzed using Student's t-test for parametric data and the Mann-Whitney U test for nonparametric data. Data was analyzed using SPSS version 20 A p value <0.05 was considered significant.

3. Results

Twelve cases of *M. bovis* infection were diagnosed in the period evaluated, which were initially classified as *M. tuberculosis* infection since they presented a positive Xpert MTB/RIF® result of some anatomical site, but all of them were later diagnosed as *M. bovis* infection by multiplex PCR assay or culture. Characteristics were compared with fourteen cases of *M. tuberculosis* infection diagnosed by culture in the same hospital during the same period. Sociodemographic characteristics showed two significant differences between both groups, the habitual consumption of unpasteurized dairy products (a risk factor for *M. bovis* infection) and a higher median CD4 T cell count in subjects with *M. bovis* infection vs. *M. tuberculosis* infection ($p < 0.0001$ and < 0.01 respectively) (**Table 1**).

Table 1. Sociodemographic characteristics of patients with *M. bovis* vs. *M. tuberculosis* infection in HIV-infected subjects.

Characteristics	<i>M. bovis</i> n=12	<i>M. tuberculosis</i> n=14	<i>p</i> value
Mean age, years (SD)	39.64±8.86	38.3±9.25	ns
Gender			
Male	10	14	ns
Female	2	0	
Regular consumption of unpasteurized dairy products (milk, artisan cheeses)	9	0	<0.0001
Recent contact with people infected with tuberculosis	1	2	ns
Drinking alcohol	6	7	ns
Current smoking	4	10	ns
Diabetes mellitus	1	0	ns
Charlson Index	6.25	6.2	ns
Absolute CD4+ T Cell count/ μ L, median (IQR)	102.5 (38-165)	20.5 (14.5-43)	0.01
HIV-1 RNA (copies/mL), median (IQR)	176260 (229-300750)	154000 (74600-683264)	ns

Abbreviations: SD, standard deviation; IQR, interquartile range; ns, not significant. Qualitative variables were analyzed using Fisher's exact test. Quantitative variables were analyzed using Student's t-test for parametric data (age) and Mann-Whitney U tests for nonparametric data (CD4 and HIV-1 RNA). A *p* value < 0.05 was considered significant.

No differences were found in symptoms, except for neurological symptoms, which were significantly more frequent in *M. tuberculosis* infection vs *M. bovis* infection ($p < 0.03$). Extrapulmonary involvement was significantly more frequent in *M. bovis* infection, while pulmonary involvement was significantly more frequent in *M. tuberculosis* infection ($p < 0.01$). All cases (100%) of *M. bovis* infection presented extrapulmonary disease. Several abdominal CT findings were significantly more frequently found in *M. bovis* infection vs. *M. tuberculosis* infection, including retroperitoneal lymphadenopathy ($p = 0.01$), hepatomegaly ($p = 0.001$), splenomegaly ($p < 0.001$), and splenic abscesses ($p = 0.004$). The site of isolation/molecular identification was significantly more frequent extrapulmonary in *M. bovis* infection (mainly from cervical or retroperitoneal lymph nodes samples, and spleen or psoas abscesses) vs *M. tuberculosis*, meanwhile the site of isolation was more frequent pulmonary in *M. tuberculosis* infection ($p = 0.01$) (**Table 2**).

Table 2. Clinical, imaging and microbiological characteristics of patients with *M. bovis* vs *M. tuberculosis* infection in HIV-infected subjects.

Characteristics	<i>M. bovis</i> n=12	<i>M. tuberculosis</i> n=14	p Value
Presenting symptoms			
Fever	10	8	ns
Cough	8	6	ns
Weight loss (>10%)	7	11	ns
Cervical lymphadenopathy	11	10	ns
Gastrointestinal (abdominal pain, diarrhea, vomiting)	8	12	ns
Neurological	1	7	0.03
Anatomical sites of involvement			
Pulmonary	1	6	0.01
Extrapulmonary	12	8	0.01
Pulmonary and extrapulmonary	1	2	ns
Pulmonary CT findings			
Miliary	0	5	0.01
Cavitations	1	3	ns
Bronchiectasis	1	1	ns
Abdominal CT findings			
Retroperitoneal lymphadenopathy	9	3	0.01
Psoas abscess	4	2	ns
Hepatomegaly	7	0	0.001
Splenomegaly	8	0	<0.001
Splenic abscesses	6	0	0.004
Site of isolation/molecular identification			
Pulmonary†	0	12	<0.0001
Neck lymph nodes	9	2	0.04
Abdominal‡	5	0	0.01
Genitourinary	1	0	ns

Abbreviations: CT, computed tomography; ns, not significant. Qualitative variables were analyzed using Fisher's exact test. A p value <0.05 was considered significant. †Includes sputum, bronchoalveolar lavage, gastric aspirate. ‡ Includes peritoneal/retroperitoneal, liver, spleen, psoas and stool samples.

Positive cultures were found in only 4 cases (33.3%) of *M. bovis* infection, the remaining were identified by molecular methods, while the 14 cases of *M. tuberculosis* infection were identified by positive cultures. Due to the sites of involvement of *M. bovis* infection, a surgical procedure (percutaneous catheter placement (n=2), open surgery (n=6), or splenectomy n=5) was performed in 8 patients (66.6%) vs none in *M. tuberculosis* infection (p <0.0003) for drainage/removal of abdominal abscesses with diagnostic and treatment purposes. No differences were found in treatment failure, relapse or mortality between both groups (**Table 3**).

Table 3. Surgical procedures and outcomes of patients with *M. bovis* vs *M. tuberculosis* infection in HIV-infected subjects.

Characteristics	<i>M. bovis</i> n=12	<i>M. tuberculosis</i> n=14	p value
Surgical procedure†	8	0	0.0003
Outcomes			
Cured	8	7	ns
Treatment failed	2	2	ns

Lost to follow-up	1	3	ns
Died	1	2	ns

Qualitative variables were analyzed using Fisher's exact test. A p value <0.05 was considered significant. † A surgical procedure was performed for diagnostic and treatment purposes, either percutaneous catheter placement, open surgery, or splenectomy for drainage/removal of abdominal abscesses.

4. Discussion

We examined the sociodemographic, clinical, microbiological characteristics, and outcomes in a series of cases of *M. bovis* infection and compared these characteristics with those of *M. tuberculosis* infection in HIV-infected subjects. Overall, we found a significantly increased risk of *M. bovis* transmission due to consumption of unpasteurized dairy products and higher CD4+ T cells count in subjects with *M. bovis* infection. There was a significantly greater incidence of extrapulmonary involvement, with more frequent retroperitoneal involvement, hepatosplenomegaly, and splenic abscesses, in subjects with *M. bovis* infection. Indeed, all subjects with *M. bovis* infection had extrapulmonary involvement, and the site of microbiological identification was extrapulmonary in all subjects. Surgical interventions such as surgical drainage of abscesses or splenectomy were required significantly more frequently in subjects with *M. bovis* infection.

The zTB burden of all TB cases shows a wide range of proportions globally [5]. The unavailability of appropriate methods for the identification of *M. bovis* in many middle and low-resource countries leads to an underestimation of the prevalence [21]. A recent meta-analysis of 19 studies and 7184 MTBC isolates found a vast difference in proportions of *M. bovis* infection in individual studies that ranged from 0.42% to 76.7%. The prevalence of studies that used conventional methods for the identification of *M. bovis* was 47.1%, while the prevalence of those that used genotypic methods was 1.4%. This discrepancy in prevalence might indicate an incorrect identification with the methods used [23].

Lowenstein-Jensen (LJ) solid medium for culture of *M. tuberculosis* supplemented with glycerol inhibits the growth of *M. bovis*. Stonebrick medium (supplemented with pyruvate) promotes the most rapid growth of *M. bovis*, however, culture on this medium is not frequently used, nor are biochemical identification methods [24]. However, liquid culture systems such as the BACTEC Mycobacteria Growth Indicator tube (MGIT) 960 which employs a fluorometric detection system overcome the problem with the LJ [25]

Culture and biochemical identification of *M. bovis* is time-consuming and infrequently performed in many laboratories. Several rapid molecular methods PCR-based have been developed to differentiate *M. bovis* from *M. tuberculosis* such as PCR targeting *oxyR* gene [26], multiplex-PCR based on a 500-bp fragment and the *pncA* gene [27], multiplex-PCR based on simultaneous detection of *pncA* 169C > G change in *M. bovis* and the IS6110 present in MTBC [28], PCR *pncA*-restriction fragment length polymorphism and PCR based on 3 regions of difference (RD-PCR): RD9, RD4 and RD1 [29]; PCR with confronting two-primers (PCR-CTPP) targeting the *lepB* gene [30], or that identify eight specific MTBC members using genomic regions of difference (RD1, RD1mic, RD2seal, RD4, RD9 and RD12) [31]. However, these methods are rarely available in most laboratories in low and middle-income countries.

One health approach to reduce the risk transmission of zTB should be implemented globally [9,14], because the consumption of raw milk and artisan cheeses is a very common practice mainly in middle and low-income countries [32]. In the United States, around 90% of *M. bovis* infection cases occur in Hispanic people and are attributed to the consumption of cheese made from unpasteurized milk in Mexico [11,33,34]. In our report, 9/12 (75%) patients with *M. bovis* infection had at least one risk factor for infection, either raw milk consumption or frequent consumption of soft artisanal cheese.

The rate of detection of *M. bovis* in fresh unpasteurized cheeses is variable, Cezar et al. found genetic material of *M. bovis* in 2.8% of 107 artisanal cheeses obtained from grocery stores and markets [10], while Barros de Melo et al. detected *M. bovis* DNA in 17.5% of samples de cheeses confiscated

from baggage of incoming travelers to Brazil [13]. On the other hand, an experimental study showed that *M. bovis* cultured in raw souring milk samples at high concentrations (107 cfu/mL) can survive for at least 2 weeks at 20°C [35]. In addition, viable bacilli have been found in yogurt and cream cheese made from raw milk for up to 14 days and up to 100 days in butter [36].

Various factors have been associated with *M. bovis* infection. A nationwide US study found 165 (1.4%) of 11,860 human TB cases, were caused by *M. bovis*. The multivariate analysis of the study identified that subjects born outside the United States, Hispanic ethnicity, age <15 years, HIV infection, and having extrapulmonary disease were associated with *M. bovis* infection versus *M. tuberculosis* [33]. In a study in a Mexican population, Torres-Gonzalez et al. found that younger age, use of glucocorticoids, and extrapulmonary disease were independently associated with *M. bovis* infection compared to *M. tuberculosis* infection [37].

Tb caused by *M. bovis* is frequently indistinguishable from *M. tuberculosis*, clinically, radiologically, and pathologically [9]. A systematic review of eight studies found a higher proportion of extrapulmonary involvement in zTB than in cases of *M. tuberculosis* infection (median 63% vs 22%, $p = 0.008$). Lymph nodes and the genitourinary system were the sites most frequently affected, followed by bones and joints, intestine and peritoneum, and the nervous system [38]. In our case series, all patients with *M. bovis* infection had extrapulmonary disease (100%) with pulmonary involvement in 6 patients (50%). Cervical lymphadenopathy was present in 11 cases (91.6%), retroperitoneal lymphadenopathy in 9 (75%), splenomegaly in 8 patients (66.6%), hepatomegaly in 7 patients (58.3%), spleen abscesses in 6 subjects (50%) and psoas abscesses in 4 cases (33.3%). In a multivariate analysis of a study of HIV and tuberculosis coinfection, it was found that in addition to being male and Hispanic ethnicity, abdominal disease was associated with *M. bovis* infection [39].

The higher association of extrapulmonary involvement of *M. bovis* infection compared with TB caused by *M. tuberculosis* is related to the route of transmission, the alimentary route through the consumption of unpasteurized dairy products leads to extrapulmonary forms of *M. bovis* infection [36]. Adults at professional risk, especially farmers, abattoir workers and veterinarians, are more frequently infected with *M. bovis* by the airborne route through aerosols from infected cattle [40]. Pulmonary disease caused by *M. bovis* has been more frequently found in subjects with occupational vs non-occupational exposure (17/17, 100% vs. 6/9, 67%; $P = 0.03$, respectively) [41].

Few studies have evaluated the prevalence and clinical characteristics of TB caused by *M. bovis* in HIV-infected individuals. An increased proportion of zTB has been reported in HIV-infected compared to HIV-uninfected subjects in studies from the United States (RR= 2.6-8.3 times higher in HIV positive vs HIV negative) [5].

A study found that of 86 cases of HIV and TB coinfection, where 34.9% were caused by *M. bovis*, a more advanced state of immunosuppression was found in *M. bovis* infection (17.9% of *M. tuberculosis* infection cases had >200 CD4+ T cell count/ μ L vs 0% of *M. bovis* infection, $p=0.01$) [39]. Contrary to our report, although we found that 91.6% of subjects with *M. bovis* infection had CD4+ T cells <200 cells/ μ L, subjects with *M. tuberculosis* infection had significantly lower median CD4 T cells than subjects with *M. bovis* infection.

A study reported higher mortality in *M. bovis* infection compared to *M. tuberculosis* infection (15% vs 7%), particularly, higher death rates occurred in HIV-infected subjects with *M. bovis* disease vs *M. tuberculosis* (28% vs 8%, $p=0.006$) [42]. Higher mortality in HIV+ vs HIV- (85%, 6/7 vs. 6%, 1/18; $P = 0.01$) was observed in a study in *M. bovis* infection in Argentina [41]. In our report, only 1 patient (8.3%) died of complications related to *M. bovis* infection. It is important to emphasize that aggressive treatment with surgical drainage of abscesses or splenectomy was performed in many subjects infected with *M. bovis* in our study, given the high number of abdominal (including psoas) and splenic abscesses that the subjects presented.

Our study has some limitations. The retrospective design leads to potential selection and reporting biases and challenges in establishing causality. The sample size is small due to the difficulties in diagnosing *M. bovis* infection. The study only included HIV-infected individuals, a state

of immunosuppression that can lead to different clinical presentations and outcomes than the general population. Therefore, the results cannot be extrapolated to the HIV-negative population.

5. Conclusions

M. bovis infection is underdiagnosed due to lack of routine of zTb and bovine TB surveillance and limited laboratory capacities representing a great challenge in public health. HIV-infected subjects are more susceptible to mycobacterial infections, accordingly, identification of *M. bovis* is particularly important. Extrapulmonary involvement is a key factor in diagnosing *M. bovis* infection in HIV-infected individuals. Surgical interventions are frequently required for diagnosis and management. Efforts to ensure appropriate identification and timely and appropriate management, particularly in regions with limited resources and high burden of *M. bovis* infection.

Author Contributions: For research articles with several authors, a short paragraph specifying their individual contributions must be provided. The following statements should be used “Conceptualization, F.A.-L. and S. Z-Q.; methodology, M.A.-Z. and P.M.-A.; software, M.A.-Z.; validation, F.A.-L., P.M.-A. and L.A.G.-H.; formal analysis, M.A.-Z.; investigation, ID.V.G.-G.; resources, F.A.-L.; data curation, S. Z-Q.; writing—original draft preparation, S. Z-Q.; writing—review and editing, F.A.-L.; visualization, J.F.A.-V.; supervision, F.A.-L.; project administration, L.A.G.-H.; funding acquisition, J.F.A.-V. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of Hospital Civil de Guadalajara for studies involving humans.

Informed Consent Statement: Patient informed consent was waived as this was a retrospective analysis of de-identified data. The IRB provided a waiver of informed consent and an IRB exemption for this purpose.

Data Availability Statement: All relevant data are within the paper.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Grange JM, Yates MD, Kantor IN de, Emerging WHOrganization, other Communicable Diseases S, Control. Guidelines for speciation within the Mycobacterium tuberculosis complex / John M. Grange, Malcolm D. Yates and Isabel N. de Kantor. 2nd ed. World Health Organization; 1996. p. Revised edition of doc. WHO/Zoon./94.174.
2. World Health Organization. Global tuberculosis report 2019.]. [cited 2025 Apr 17]. Available from: <https://www.who.int/publications/i/item/global-tuberculosis-report-2019>
3. Kock R, Michel AL, Yeboah-Manu D, Azhar EI, Torrelles JB, Cadmus SI, et al. Zoonotic Tuberculosis – The Changing Landscape. International Journal of Infectious Diseases. 2021 Dec;113:S68–72.
4. Olea-Popelka F, Muwonge A, Perera A, Dean AS, Mumford E, Erlacher-Vindel E, et al. Zoonotic tuberculosis in human beings caused by Mycobacterium bovis – a call for action. Lancet Infect Dis. 2017 Jan;17(1):e21–5.
5. Müller B, Dürr S, Alonso S, Hattendorf J, Laise CJM, Parsons SDC, et al. Zoonotic *Mycobacterium bovis* – induced Tuberculosis in Humans. Emerg Infect Dis. 2013 Jun;19(6):899–908.
6. Grange JM. Mycobacterium bovis infection in human beings. Tuberculosis. 2001 Feb;81(1–2):71–7.
7. Dankner WM, Waecker NJ, Essey MA, Moser K, Thompson M, Davis CE. Mycobacterium bovis infections in San Diego: a clinicoepidemiologic study of 73 patients and a historical review of a forgotten pathogen. Medicine. 1993 Jan;72(1):11–37.

8. Laniado-Laborín R, Muñiz-Salazar R, García-Ortiz RA, Vargas-Ojeda AC, Villa-Rosas C, Ocegüera-Palao L. Molecular characterization of *Mycobacterium bovis* isolates from patients with tuberculosis in Baja California, Mexico. *Infection, Genetics and Evolution*. 2014 Oct;27:1–5.
9. Macedo Couto R, Ranzani OT, Waldman EA. Zoonotic Tuberculosis in Humans: Control, Surveillance, and the One Health Approach. *Epidemiol Rev*. 2019 Jan 31;41(1):130–44.
10. Cezar RDS, Lucena-Silva N, Borges JM, Santana VLA, Pinheiro Junior JW. Detection of *Mycobacterium bovis* in artisanal cheese in the state of Pernambuco, Brazil. *Int J Mycobacteriol*. 2016 Sep;5(3):269–72.
11. Ortiz AP, Perea C, Davalos E, Velázquez EF, González KS, Camacho ER, et al. Whole Genome Sequencing Links *Mycobacterium bovis* From Cattle, Cheese and Humans in Baja California, Mexico. *Front Vet Sci*. 2021 Aug 3;8.
12. Harris NB, Payeur J, Bravo D, Osorio R, Stuber T, Farrell D, et al. Recovery of *Mycobacterium bovis* from Soft Fresh Cheese Originating in Mexico. *Appl Environ Microbiol*. 2007 Feb;73(3):1025–8.
13. Barros de Melo C, Pinheiro de Sá ME, Souza A dos R, Macedo de Oliveira A, Mota PMPC, Campani PR, et al. Bacteria in Dairy Products in Baggage of Incoming Travelers, Brazil. *Emerg Infect Dis*. 2014 Nov;20(11):1933–5.
14. de Macedo Couto R, Santana GO, Ranzani OT, Waldman EA. One Health and surveillance of zoonotic tuberculosis in selected low-income, middle-income and high-income countries: A systematic review. *PLoS Negl Trop Dis*. 2022 Jun 6;16(6):e0010428.
15. Romha G, Gebru G, Asefa A, Mamo G. Epidemiology of *Mycobacterium bovis* and *Mycobacterium tuberculosis* in animals: Transmission dynamics and control challenges of zoonotic TB in Ethiopia. *Prev Vet Med*. 2018 Oct;158:1–17.
16. Gonzalo-Asensio J, Malaga W, Pawlik A, Astarie-Dequeker C, Passemar C, Moreau F, et al. Evolutionary history of tuberculosis shaped by conserved mutations in the PhoPR virulence regulator. *Proceedings of the National Academy of Sciences*. 2014 Aug 5;111(31):11491–6.
17. Cobo J, Asensio A, Moreno S, Navas E, Pintado V, Oliva J, et al. Risk factors for nosocomial transmission of multidrug-resistant tuberculosis due to *Mycobacterium bovis* among HIV-infected patients. *Int J Tuberc Lung Dis*. 2001 May;5(5):413–8.
18. Bouvet E, Casalino E, Mendoza-Sassi G, Lariven S, Vallée E, Pernet M, et al. A nosocomial outbreak of multidrug-resistant *Mycobacterium bovis* among HIV-infected patients. *AIDS*. 1993 Nov;7(11):1453–60.
19. Rivero A, Marquez M, Santos J, Pinedo A, Sanchez MA, Esteve A, et al. High Rate of Tuberculosis Reinfection during a Nosocomial Outbreak of Multidrug-Resistant Tuberculosis Caused by *Mycobacterium bovis* Strain B. *Clinical Infectious Diseases*. 2001 Jan 1;32(1):159–61.
20. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update [Internet]. [cited 2023 Apr 17]. Available from: <https://apps.who.int/iris/handle/10665/112472>
21. Roadmap for zoonotic tuberculosis [Internet]. [cited 2025 Apr 17]. Available from: <https://apps.who.int/iris/handle/10665/259229>
22. WHO consolidated guidelines on tuberculosis Module 4: Treatment Drug-susceptible tuberculosis treatment. [cited 2025 Apr 17]. Available from: <https://www.who.int/publications/i/item/9789240050761>
23. Taye H, Alemu K, Mihret A, Wood JLN, Shkedy Z, Berg S, et al. Global prevalence of *Mycobacterium bovis* infections among human tuberculosis cases: Systematic review and meta-analysis. *Zoonoses Public Health*. 2021 Nov 24;68(7):704–18.
24. Bolaños CAD, Paula CL de, Guerra ST, Franco MMJ, Ribeiro MG. Diagnosis of mycobacteria in bovine milk: an overview. *Rev Inst Med Trop Sao Paulo*. 2017;59(0).
25. Robbe-Austerman S, Bravo DM, Harris B. Comparison of the MGIT 960, BACTEC 460 TB and solid media for isolation of *Mycobacterium bovis* in United States veterinary specimens. *BMC Vet Res*. 2013;9(1):74.
26. Portillo-Gómez L, Sosa-Iglesias EG. Molecular identification of *Mycobacterium bovis* and the importance of zoonotic tuberculosis in Mexican patients. *The International Journal of Tuberculosis and Lung Disease*. 2011 Oct 1;15(10):1409–14.

27. Shah DH, Verma R, Bakshi CS, Singh RK. A multiplex-PCR for the differentiation of *Mycobacterium bovis* and *Mycobacterium tuberculosis*. FEMS Microbiol Lett. 2002 Aug;214(1):39–43.
28. Sposito FLE, Campanerut PAZ, Ghiraldi LD, Leite CQF, Hirata MH, Hirata RDC, et al. Multiplex-PCR for differentiation of *Mycobacterium bovis* from *Mycobacterium tuberculosis* complex. Brazilian Journal of Microbiology. 2014 Sep;45(3):841–3.
29. Bouzouita I, Draoui H, Mahdhi S, Essalah L, Slim Saidi L. Evaluation of PCR pncA-restriction fragment length polymorphism and PCR amplification of genomic regions of difference for the identification of *M. bovis* strains in lymph nodes cultures. Afr Health Sci. 2021 Sep 27;21(3):985–9.
30. Sitthidet Tharinjaroen C, Intorasoot S, Anukool U, Phunpae P, Butr-Indr B, Orrapin S, et al. Novel targeting of the lepB gene using PCR with confronting two-pair primers for simultaneous detection of *Mycobacterium tuberculosis* complex and *Mycobacterium bovis*. J Med Microbiol. 2016 Jan 1;65(1):36–43.
31. Warren RM, Gey van Pittius NC, Barnard M, Hesselting A, Engelke E, de Kock M, et al. Differentiation of *Mycobacterium tuberculosis* complex by PCR amplification of genomic regions of difference. Int J Tuberc Lung Dis. 2006 Jul;10(7):818–22.
32. Kapoor S, Goel AD, Jain V. Milk-borne diseases through the lens of one health. Front Microbiol. 2023 Apr 6;14.
33. Hlavsa MC, Moonan PK, Cowan LS, Navin TR, Kammerer JS, Morlock GP, et al. Human Tuberculosis due to *Mycobacterium bovis* in the United States, 1995–2005. Clinical Infectious Diseases. 2008 Jul 15;47(2):168–75.
34. Human Tuberculosis Caused by *Mycobacterium bovis*: New York City, 2001–2004. Pediatr Infect Dis J [Internet]. 2005;24(10). Available from: https://journals.lww.com/pidj/Fulltext/2005/10000/Human_Tuberculosis_Caused_by_Mycobacterium_bovis_.29.aspx
35. Michel AL, Geoghegan C, Hlokw T, Raseleka K, Getz WM, Marcotty T. Longevity of *Mycobacterium bovis* in Raw and Traditional Souring Milk as a Function of Storage Temperature and Dose. PLoS One. 2015 Jun 29;10(6):e0129926.
36. de la Rúa-Domenech R. Human *Mycobacterium bovis* infection in the United Kingdom: Incidence, risks, control measures and review of the zoonotic aspects of bovine tuberculosis. Tuberculosis. 2006 Mar;86(2):77–109.
37. Torres-Gonzalez P, Cervera-Hernandez ME, Martinez-Gamboa A, Garcia-Garcia L, Cruz-Hervert LP, Bobadilla-del Valle M, et al. Human tuberculosis caused by *Mycobacterium bovis*: a retrospective comparison with *Mycobacterium tuberculosis* in a Mexican tertiary care centre, 2000–2015. BMC Infect Dis. 2016 Dec 8;16(1):657.
38. Dürr S, Müller B, Alonso S, Hattendorf J, Laise CJM, van Helden PD, et al. Differences in Primary Sites of Infection between Zoonotic and Human Tuberculosis: Results from a Worldwide Systematic Review. PLoS Negl Trop Dis. 2013 Aug 29;7(8):e2399.
39. Park D, Qin H, Jain S, Preziosi M, Minuto JJ, Mathews WC, et al. Tuberculosis due to *Mycobacterium bovis* in Patients Coinfected with Human Immunodeficiency Virus. Clinical Infectious Diseases. 2010 Dec;51(11):1343–6.
40. Biet F, Boschirola ML, Thorel MF, Guilloteau LA. Zoonotic aspects of *Mycobacterium bovis* and *Mycobacterium avium-intracellulare* complex (MAC). Vet Res. 2005 May;36(3):411–36.
41. Cordova E, Gonzalo X, Boschi A, Lossa M, Robles M, Poggi S, et al. Human *Mycobacterium bovis*; infection in Buenos Aires: epidemiology, microbiology and clinical presentation [Short communication]. The International Journal of Tuberculosis and Lung Disease. 2012 Mar 1;16(3):415–7.
42. Gallivan M, Shah N, Flood J. Epidemiology of Human *Mycobacterium bovis* Disease, California, USA, 2003–2011. Emerg Infect Dis. 2015 Mar;21(3):435–43.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.